Ultrasensitive Fluorogenic Substrates for Serine Proteases^[*]

Summary

Selective, sensitive assays for the quantitation of serine proteases involved in coagulation and fibrinolysis have been developed employing fluorogenic substrates containing a 6-amino-1-naphthalenesulfonamide leaving group (PNS-substrates). Over one hundred substrates were evaluated for hydrolysis by the serine proteases of blood coagulation and fibrinolysis, and substrate structure-efficiency correlations were examined. PNS-substrates which contain Lys in the P₁ position are specific for Lys-plasmin and are either not hydrolyzed or hydrolyzed at a relatively low rate by factor Xa, thrombin, or urokinase-type plasminogen activator (uPA). These substrates allow quantitation of Lys-plasmin at concentrations as low as 1 pM. Eighteen of over 90 substrates tested for factor XIa are hydrolyzed by this enzyme at a relatively high rate reaching a k_cat value of 170 s^-1 and allowing quantitation of factor XIa at 10 fM. Eighteen of almost 90 PNS-substrates tested display high specificity for thrombin, some exceeding that for factor Xa by > 10,000-fold and > 100-fold for activated protein C (APC). Seven of these substrates have a over 100 s^-1 and three of them have a K_M below 1 μM. They allow the quantitation of thrombin at concentrations as low as 20 fM. For APC, uPA and the factor Vila/tissue factor complex, quantitation is feasible at 1 pM concentration. For factor Xa and factor VIIa the limits are 0.4 pM and 40 pM respectively. The PNS-substrates presented in this study may be employed for the development of direct and sensitive serine protease assays.

• References

• 1 Colman RW, Hirsh J, Marder VC, Salzman EW. Hemostatis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: J. B. Lippincott Company; 1994
• 2 Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 1984; 74: 2033-2041
• 3 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744
• 4 McRae BJ, Kurachi K, Heimark RL, Fujikawa K, Davie EW, Powers JC. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor Xlla, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates. Biochemistry 1981; 20: 7196-7206
• 5 Cho K, Tanaka T, Cook RR, Kisiel W, Fujikawa K, Kurachi K, Powers JC. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates. Biochemistry 1984; 23: 644-650
• 6 Krishnaswamy S. The interaction of human factor Vila with tissue factor. J Biol Chem 1992; 267: 23696-23706
• 7 Shigematsu Y, Miyata T, Higashi S, Miki T, Sadler JE, Iwanga S. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor Vila. J Biol Chem 1992; 267: 21329-21337
• 8 Butenas S, Ribarik N, Mann KG. Syanthatic substrates for human factor Vila and factor VHa-tissue factor. Biochemistry 1993; 32: 6531-6538
• 9 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin II. An empirical study. J Biol Chem 1994; 269: 23357-23366
• 10 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin II. A mathematical simulation. J Biol Chem 1994; 269: 23367-23373
• 11 Rand MD, Lock JB, Van’t VeerC, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445
• 12 Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 1981; 256: 253-259
• 13 Bachmann F, Kruithof EKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984; 10: 06-17
• 14 Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase- type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1986; 56: 411-414
• 15 Lawson JH, Mann KG. Cooparative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 11317-11327
• 16 Astrup T, Mullertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
• 17 Kesner A, Troll W. Fluorometric microassay of plasminogen activators. Arch Biochem Biophys 1976; 176: 411-416
• 18 Seligsohn U, Østerud B, Rapaport SI. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VH. Blood 1978; 52: 978-988
• 19 Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF-VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991; 66: 529-533
• 20 Radcliffe R, Nemerson Y. Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa. J Biol Chem 1976; 251: 4797-802
• 21 Barlow GH, Francis CW, Marder VJ. On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res 1981; 23: 54-61
• 22 Gyzander E, Eriksson E, Teger-Nilsson AC. A sensitive assay for tissue plasminogen activator activity in plasma using adsorption on lysine-Sepha- rose. Thromb Res 1984; 35: 547-558
• 23 Verheijen JH, de JongYF, Chang GTG. Quantitative analysis of mixtures of one-chain and two-chain tissue-type plasminogen activator with a spectrophotometric method. Thromb Res 1985; 39: 281-288
• 24 Rao LVM, Rapaport SI. The effect of platelets upon factor Xa-catalyzed activation of factor VH in vitro. Blood 1988; 72: 396-401
• 25 Schechter I, Berger A. On the size of the active site in proteases.I. Papain. Biochem Biophys Res Com 1967; 27: 157-162
• 26 Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol 1981; 80: 341-361
• 27 Butenas S, Orfeo T, Lawson JH, Mann KG. Aminonaphthalenesulfona-mides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes. Biochemistry 1992; 31: 5399-5411
• 28 Claeson G, Aurell L, Friberger P, Gustavsson S, Karlsson G. Designing of peptide substrates. Haemostasis 1978; 7: 62-68
• 29 Castillo MJ, Kurachi K, Nishino N, Ohkubo I, Powers JC. Reactivity of bovine blood coagulation factor IXa, factor Xa, and factor XIa toward fluorogenic peptides containing the activation sites sequences of bovine factor IX and factor X. Biochemistry 1983; 22: 1021-1029
• 30 Zimmerman M, Yurewicz E, Patel G. A new fluorogenic substrate for chymotrypsin. Anal Biochem 1976; 70: 258-262
• 31 Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epiderman growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C- activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264: 10351-10353
• 32 Horie S, Ishi H, Hara H, Kazama M. Enhancement of thrombin-thrombomodulin-catalyzed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem J 1994; 301: 683-691
• 33 Miyata T, Funatsu A, Kato H. Chemical cross-linking of activated coagulation factor VH with soluble tissue factor calcium ions are not essential for full amidolytic activity of the factor VDa-tissue factor complex after complex formation. J Biochem 1995; 117: 836-844
• 34 Butenas S, Drungilaite V, Mann KG. Fluorogenic substrates for activated protein C: substrate structure-efficiency correlation. Anal Biochem 1995; 225: 231-241
• 35 Higgins DL, Mann KG. The interaction of bovine factor V and factor V-de- rived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-6508
• 36 Lawson JH, Krishnaswamy S, Butenas S, Mann KG. Proteolytic activity of the extrinsic pathway. Methods Enzymol 1993; 222: 177-194
• 37 Butenas S, Mann KG. Keinetics of human factor VH activation. Biochemistry 1996; 35: 1904-1910
• 38 Kolde HJ, Eberle R, Heber H, Heimburger N. New chromogenic substrates for thrombin with increased specificity. Thromb Haemost 1986; 56: 155-159
• 39 Weinstein MJ, Doolittle RF. specificities of thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors. Biochim Biophys Acta 1972; 258: 577-590
• 40 Pierzchala PA, Dorn CP, Zimmerman M. A new fluorogenic substrate for plasmin. Biochem J 1979; 183: 555-559
• 41 Kato H, Adachi N, Ohno Y, Iwanaga S, Takada K, Sakakibara S. New fluorogenic peptide substrates for plasmin. J Biochem 1980; 88: 183-190
• 42 Kiss I, Aurell L, Pozsgay M, Elodi P. Investigation on the substrate specificity of human plasmin using tripeptidyl-p-nitroanilide substrates. Biochem Biophys Res Commun 1985; 131: 928-934
• 43 Hamois-Pontoni M, Monsigny M, Mayer R. Hydrosoluble fluorogenic substrates for plasmin. Anal Biochem 1991; 193: 248-255
• 44 Butenas S, Kalafatis M, Mann KG. Analysis of tissue plasminogen activator specificity using peptidyl fluorogenic substrates. Biochemistry 1997; 36: 2123-2131
• 45 Lottenberg R, Hall JA, Blinder EP, Jackson CM. The action of thrombin on peptide p-nitroenilide substrates. Substrate selectivity and examination of hydrolysis under different reaction conditions. Biochim Biophys Acta 1983; 742: 539-557
• 46 Rezaie WR, Esmon CT. Convertion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. J Biol Chem 1993; 268: 19943-19948
• 47 Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, Maraganore JM, Fenton II JW. Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. Biochemistry 1992; 31: 11689-11697
• 48 Le BonniecBF, Myles T, Johnson T, Knight CG, Tapparelli C, Stone SR. Characterization of the P₂' and P₃' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Biochemistry 1996; 35: 7114-7122
• 49 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89
• 50 Wun T-C, Schleuning W-D, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
• 51 von demBorne PA, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemostasis 1994; 72: 397-402
• 52 Andreasen PA, Petersen LC, Dana K. Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator. Fibrinolysis 1991; 5: 207-215